Celgene shaken again after the FDA kicks back their marketing application on blockbuster hopeful ozanimod

Celgene has been slammed with a refuse-to-file letter from the FDA for ozanimod, the biggest late-stage drug it has in the pipeline.

• Source: endpts
• 690
• March 2, 2018